The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Phage display screening of therapeutic peptide for cancer targeting and therapy
Open accessAbstract
Recently, phage display technology has been announced as the recipient of Nobel Prize in Chemistry 2018. Phage display technique allows high affinity target-binding peptides to be selected from a complex mixture pool of billions of displayed peptides on phage in a combinatorial library and could be further enriched through the biopanning process; proving to be a powerful technique in the screening of peptide with high affinity and selectivity. In this review, we will first discuss the modifications in phage display techniques used to isolate various cancer-specific ligands by in situ,in vitro,in vivo, and ex vivo screening methods. We will then discuss prominent examples of solid tumor targeting-peptides; namely peptide targeting tumor vasculature, tumor microenvironment (TME) and over-expressed receptors on cancer cells identified through phage display screening. We will also discuss the current challenges and future outlook for targeting peptide-based therapeutics in the clinics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Saw, P. E., Park, J., Jon, S., & Farokhzad, O. C. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.10.005 · Cited by 43
Self-citationKim, H., Lee, Y., Lee, I.-H., Kim, S.-H., Kim, D., Saw, P. E., Lee, J., Choi, M., Kim, Y. C., & Jon, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.01.015 · Cited by 41
Self-citationRen, H., Gao, C., Zhou, L., Liu, M., Xie, C., & Lu, W. (2014) · Drug Delivery · doi:10.3109/10717544.2014.896057 · Cited by 35
Kwon, M.-K., Nam, J.-O., Park, R., Lee, B.-H., Park, J., Byun, Y., Kim, S., Kwon, I. C., & Kim, I.-S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2009 · Cited by 33
Segers, F. M., Yu, H., Molenaar, T. J. M., Prince, P., Tanaka, T., van Berkel, T. J. C., & Biessen, E. A. L. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.235358 · Cited by 32
Ujula, T., Huttunen, M., Luoto, P., Peräkylä, H., Simpura, I., Wilson, I., Bergman, M., & Roivainen, A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc1000643 · Cited by 31
Zanini, E., Louis, L. S., Antony, J., Karali, E., Okon, I. S., McKie, A. B., Vaughan, S., El-Bahrawy, M. A., Stebbing, J., Recchi, C., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0081 · Cited by 30
Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer
Arnold, S. A., Loomans-Kropp, H. A., Ketova, T., Andl, C. D., Clark, P. E., & Zijlstra, A. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9754-x · Cited by 26
Targeting of the epidermal growth factor receptor with mesoporphyrin IX-peptide conjugates
Fontenot, K. R., Ongarora, B. G., LeBlanc, L. E., Zhou, Z., Jois, S. D. S., & Vicente, M. G. H. (2016) · Journal of Porphyrins and Phthalocyanines · doi:10.1142/s1088424616500115 · Cited by 24
Self-assembled nanoparticles comprising aptide–SN38 conjugates for use in targeted cancer therapy
Kim, H., Lee, Y., Kang, S., Choi, M., Lee, S., Kim, S., Gujrati, V., Kim, J., & Jon, S. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/48/48lt01 · Cited by 21
Suzuki, H., Sasada, M., Kamiya, S., Ito, Y., Watanabe, H., Okada, Y., Ishibashi, K., Iyoda, T., Yanaka, A., & Fukai, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010181 · Cited by 20
Fan, M., Liang, X., Yang, D., Pan, X., Li, Z., Wang, H., & Shi, B. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1058800 · Cited by 18
HER2-specific aptide conjugated magneto-nanoclusters for potential breast cancer imaging and therapy
Park, J., Park, S., Kim, S., Lee, I.-H., Saw, P. E., Lee, K., Kim, Y., Kim, Y., Farokhzad, O. C., Jeong, Y. Y., et al. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20613k · Cited by 18
Self-citationYang, F., Ai, W., Jiang, F., et al. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.10.020 · Cited by 15
Jeon, H., Kim, D., Choi, M., Kang, S., Kim, J. Y., Kim, S., & Jon, S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00520 · Cited by 11
Overexpression of PITPNM3 promotes hepatocellular carcinoma cell metastasis
He, C., Su, S., Chen, F., Huang, D., Zheng, F., Huang, W., Chen, J., Cui, X., Liu, Q., Song, E., et al. (2014) · Chinese Science Bulletin · doi:10.1007/s11434-014-0183-z · Cited by 6
Self-citation(2003) · PubMed
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy
Li, J., Wang, Q., Xia, G., Adilijiang, N., Li, Y., Hou, Z., Fan, Z., & Li, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092233 · Cited by 278
Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy
Lin, Y., Yan, M., Bai, Z., Xie, Y., Ren, L., Wei, J., Zhu, D., Wang, H., Liu, Y., Luo, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01636-x · Cited by 125
“Phage display has been used for performing high-throughput screening and identifying functional peptide ligands for various targets, including PD-L1 [28], tumor stromal cells [29], and ischemic myocardial tissues [30].”
MethodPeptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Bacteriophages as Solid Tumor Theragnostic Agents
Veeranarayanan, S., Azam, A. H., Kiga, K., Watanabe, S., & Cui, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010402 · Cited by 39
Metadata
- Authors
- Saw, P. E., & Song, E.-W.
- Venue
- Protein & Cell
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-28
- Volume
- 10
- Issue
- 11
- Pages
- 787-807
- ISSN
- 1674-800X (ISSN-L)
- 1674-8018
- OpenAlex
- W2947027538
- Cited by
- 279
- References
- 217
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.